tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mohamed MA et al. | The effect of cyclosporin A and tacrolimus on cultured human epithelial cells: the role of TGF-beta. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083523 |
| Yamashita K et al. | Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083526 |
| Wu MS et al. | Cyclosporine, but not FK506 and rapamycin, enhances Na(+)-K(+)-CL- cotransport activity in cultured medullary thick ascending limb cells. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083527 |
| Schorlemmer HU et al. | Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083529 |
| Jiang H et al. | Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083538 |
| Hoshino Y et al. | FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083547 |
| Chiba K et al. | FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083549 |
| Fu F et al. | Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083555 |
| Cirocco RE et al. | Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083604 |
| Vieregge B et al. | Synergistic effects of the alkaloid sinomenine in combination with the immunosuppressive drugs tacrolimus and mycophenolic acid. | 1999 | Planta Med. | pmid:10083851 |
| Shapiro R | Tacrolimus in pediatric renal transplantation: a review. | 1998 | Pediatr Transplant | pmid:10084728 |
| Atkison P et al. | Small bowel transplantation in children. | 1997 | Pediatr Transplant | pmid:10084770 |
| Webber SA | 15 years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects. | 1997 | Pediatr Transplant | pmid:10084782 |
| Yura H et al. | Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. | 1999 | J Control Release | pmid:10084872 |
| Trimbur GM et al. | Cloning, sequencing, and nucleolar targeting of the basal-body-binding nucleolar protein BN46/51. | 1999 | J. Cell. Sci. | pmid:10085251 |
| Liang J et al. | Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. | 1999 | Acta Crystallogr. D Biol. Crystallogr. | pmid:10089303 |
| Crabtree GR | Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. | 1999 | Cell | pmid:10089876 |
| Kimura T et al. | N-glycosylation is involved in the sensitivity of Saccharomyces cerevisiae to HM-1 killer toxin secreted from Hansenula mrakii IFO 0895. | 1999 | Appl. Microbiol. Biotechnol. | pmid:10091323 |
| Nakahama H et al. | Effect of FK 506 in the treatment of autoimmune glomerulonephritis in Brown Norway rats. | 1999 | Nephron | pmid:10095178 |
| Kenyon NS et al. | Islet transplantation: present and future perspectives. | 1998 | Diabetes Metab Rev | pmid:10095999 |